Burnett Patrick 4
4 · Arcutis Biotherapeutics, Inc. · Filed Nov 5, 2025
Insider Transaction Report
Form 4
Burnett Patrick
See Remarks
Transactions
- Sale
Common Stock
2025-11-03$25.40/sh−15$381→ 102,189 total - Sale
Common Stock
2025-11-03$24.71/sh−2,607$64,425→ 102,204 total - Sale
Common Stock
2025-11-05$23.72/sh−3,864$91,643→ 98,325 total
Footnotes (4)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.52 to $23.865, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.